权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel immunotherapy against MOG antibody disease

针对 MOG 抗体疾病的新型免疫疗法

基本信息

批准号：
10547008
负责人：
Greg Barrett
金额：
$ 28.77万
依托单位：
EVOQ THERAPEUTICS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-07-15 至 2023-07-15
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10547008
关键词：
Address Anaphylaxis Antibodies Antibody titer measurement Antigen Presentation Antigen Targeting Antigens Apolipoprotein A-I Autoantibodies Autoantigens Autoimmune Diseases B-Lymphocytes Blindness Brain Chemistry Clinical Cyclic GMP Data Dendritic Cells Development Plans Diagnosis Disease Drug Kinetics Encephalomyelitis Epitopes Exhibits Experimental Autoimmune Encephalomyelitis Formulation Goals High Density Lipoproteins Homing Human IgG autoantibodies Immune Immune Tolerance Immunosuppression Immunosuppressive Agents Immunotherapy Infection Inflammation Inflammatory Interferon Type II Interleukin-17 Knowledge Lead Mediating Membrane Modeling Multiple Sclerosis Myelin Sheath Nerve Degeneration Neuraxis Neurologic Optic Nerve Patients Peptides Peripheral Blood Mononuclear Cell Phospholipids Predisposition Production Public Health Regulatory T-Lymphocyte Relapse Reporting Research Research Contracts Risk Seizures Serum Spinal Cord Steroids Symptoms T-Lymphocyte Therapeutic Toxicology Treatment Efficacy Up-Regulation associated symptom base central nervous system demyelinating disorder clinical candidate clinical development clinical translation curative treatments cytokine draining lymph node drug development effective therapy extracellular lead candidate lymph nodes meetings mouse model nanodisk novel novel strategies oligodendrocyte-myelin glycoprotein peptidomimetics programmed cell death ligand 1 response rituximab standard of care subcutaneous targeted treatment

项目摘要

PROJECT SUMMARY/ABSTRACT Myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOGAD) is a rare, neurological, immune- mediated inflammatory, demyelinating disorder of the central nervous system. The symptoms of MOGAD include vision loss, symptoms associated with damage to the spinal cord, as well as seizures. While the current standard of care against MOGAD includes steroids and immunosuppressants, they are associated with systemic immunosuppression with complications and frequent debilitating relapses. Thus, there is an urgent need for new targeted treatment options for MOGAD patients. As MOG is the sole target antigen in MOGAD patients, MOG is an attractive target for immunotherapy against MOGAD. Here, we propose to develop a novel strategy for immunotherapy against MOG. Toward this goal, we have developed synthetic high-density lipoprotein NanoDiscs that are particularly well suited for lymph node targeting. We have shown that NanoDiscs carrying antigens induce robust CD4 regulatory T cells and downregulate autoantibodies, thereby leading to antigen- specific immune tolerance in a murine model of experimental autoimmune encephalomyelitis. Based on our compelling proof-of-concept data, here we propose to further develop NanoDiscs carrying human MOG antigens and identify a lead candidate for clinical translation.

项目总结/文摘